Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 9 de 9
Filter
1.
Leukemia ; 21(3): 446-52, 2007 Mar.
Article in English | MEDLINE | ID: mdl-17205057

ABSTRACT

To determine prognosis of acute promyelocytic leukemia (APL) failing to front-line therapy with all-trans retinoic acid (ATRA) and anthracyclines, outcome of 52 patients (32 M/20 F; age: 37, 3-72) included in PETHEMA trials LPA96 and LPA99 who presented with either molecular failure (MOLrel, n=16) or hematological relapse (HEMrel, n=36) was analyzed. Salvage therapy consisted of ATRA and high-dose ara-C-based chemotherapy (HDAC) in most cases (83%), followed by stem-cell transplantation (autologous, 18; allogeneic, 10; syngeneic, 1). Fourteen patients with MOLrel (88%) achieved second molecular complete response (molCR), whereas 81% HEMrel patients responded to second-line treatment, with 58% molCR. After median follow-up of 45 months, four MOLrel and 18 HEMrel patients, respectively, experienced a second relapse. Outcome after MOLrel compared favorably to HEMrel, with longer survival (5-year survival: 64+/-14 vs 24+/-8%, P=0.01) and lower relapse risk (5-year relapse risk: 30+/-13 vs 64+/-9%; P=0.044). Additionally, age

Subject(s)
Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Leukemia, Promyelocytic, Acute/drug therapy , Salvage Therapy , Adolescent , Adult , Aged , Antineoplastic Combined Chemotherapy Protocols/administration & dosage , Biomarkers, Tumor/blood , Child , Child, Preschool , Combined Modality Therapy , Cytarabine/administration & dosage , Etoposide/administration & dosage , Female , Hematopoietic Stem Cell Transplantation , Humans , Idarubicin/administration & dosage , Kaplan-Meier Estimate , Leukemia, Promyelocytic, Acute/blood , Leukemia, Promyelocytic, Acute/mortality , Leukemia, Promyelocytic, Acute/pathology , Leukemia, Promyelocytic, Acute/surgery , Liposomes/administration & dosage , Male , Middle Aged , Mitoxantrone/administration & dosage , Neoplasm, Residual , Oncogene Proteins, Fusion/blood , Prognosis , Recurrence , Remission Induction , Survival Analysis , Time Factors , Treatment Outcome , Tretinoin/administration & dosage
3.
Med Clin (Barc) ; 110(2): 41-4, 1998 Jan 24.
Article in Spanish | MEDLINE | ID: mdl-9534129

ABSTRACT

BACKGROUND: Low grade gastric MALT lymphoma is associated to infection with Helicobacter pylori. Also, H. pylori eradication can produce histologic regression of the lymphoma. PATIENTS AND METHODS: This study reports the follow-up of a prospective series of 11 patients with low grade gastric MALT lymphoma, stage I, treated with eradicative therapy for H. pylori. After treatment, patients were followed up with sequential endoscopies to asses the histological and molecular regression of the lymphoma, using a score of the histological lesions and the amplification of the IgH gene with PCR analysis. RESULTS: Helicobacter pylori was eradicated in all patients. In 10(90.9%) histological regression of the lymphoma was demonstrated, in 6 of them in the first control after treatment. In the 10 patients with histological response, PCR analysis demonstrated a polyclonal rearrangement of the IgH gene in 6 (60%) and a clonal band in 4 (40%), that eventually disappeared at 12 (SD 4) months after treatment. In 4 patients with a previous polyclonal rearrangement, a clonal band was occasionally detected in any sequential controls; in 2 of these cases the clonal band disappeared 5 and 7 months after treatment and in the remaining 2 its evolution is not yet known. Nine patients have been followed up and are in remission 18 (SD 8) months after treatment. CONCLUSIONS: Eradication of H. pylori can produce histologic regression in stage I low grade gastric MALT lymphoma, and should be the first therapeutic option. Despite histological regression of the lymphoma, PCR analysis can detect a clonal rearrangement of the IgH gene in 40% of the cases, but its significance remains unknown. Sequential and prolonged follow-up is essential to assess whether this lymphoma can be actually cured with eradication therapy for H. pylori.


Subject(s)
Helicobacter Infections/physiopathology , Helicobacter pylori , Lymphoma, B-Cell, Marginal Zone/microbiology , Stomach Neoplasms/microbiology , Adult , Aged , Anti-Bacterial Agents/therapeutic use , Female , Follow-Up Studies , Gene Rearrangement , Helicobacter Infections/drug therapy , Humans , Immunoglobulin Heavy Chains/genetics , Lymphoma, B-Cell, Marginal Zone/genetics , Lymphoma, B-Cell, Marginal Zone/pathology , Lymphoma, B-Cell, Marginal Zone/therapy , Male , Middle Aged , Polymerase Chain Reaction , Prospective Studies , Remission Induction , Stomach Neoplasms/genetics , Stomach Neoplasms/pathology , Stomach Neoplasms/therapy
6.
Sangre (Barc) ; 34(3): 186-90, 1989 Jun.
Article in Spanish | MEDLINE | ID: mdl-2762980

ABSTRACT

Cells from three patients showed maturation after incubation with retinoic acid (2 had M-3 AML and 1 had CML-B). Three additional patients showed spontaneous maturation (1 with M-2 and 2 with M-4 AML), and in them cell maturation was also achieved after incubation with retinoic acid and cytosine arabinoside (10 nM). These results confirm different maturation capability of leukaemic cells, as well as the possibility to induce cellular maturation with retinoic acid, especially in patients with acute promyelocytic leukaemia (M-3).


Subject(s)
Leukemia, Myelogenous, Chronic, BCR-ABL Positive/pathology , Leukemia, Myeloid, Acute/pathology , Tretinoin/pharmacology , Adult , Aged , Cell Differentiation/drug effects , Cells, Cultured , Humans , Middle Aged
SELECTION OF CITATIONS
SEARCH DETAIL
...